Phase 2 Study of ADX-038 in Participants With Geographic Atrophy

Who May Qualify: - Clinical diagnosis of GA of the macula secondary to AMD - GA lesions between 2.5 and 12.5 mm2 at screening - Sufficiently clear ocular media, adequate pupillary dilation and fixation to permit quality fundus imaging in the study eye as described in the protocol - Willing and able to comply with clinic visits and study-related procedures, including completion of the full series of meningococcal vaccinations and pneumococcal vaccination required per protocol Who Should NOT Join This Trial: - Has GA secondary to causes other than AMD - Has active ocular disease that compromises or confounds visual function - History of surgery for retinal detachment - Has ocular condition other than GA secondary to AMD - Use of intravitreal complement inhibitors in study eye - Hereditary or acquired complement deficiency - Active viral, bacterial or fungal infection - Liver injury as evidenced by abnormal liver function tests - Donating blood - History of choroidal neovascularization in the study eye Always talk to your doctor about whether this trial is right for you.